欧洲抗体药物偶联物市场预测至 2030 年 - 区域分析 - 按技术(可裂解接头和不可裂解接头)、应用(血癌、乳腺癌、卵巢癌、尿路上皮癌等)和分销渠道(医院药房、零售)药房和网上药房)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030


No. of Pages: 104    |    Report Code: BMIRE00029768    |    Category: Life Sciences

Europe Antibody Drug Conjugates Market
2022年欧洲抗体药物偶联物市场价值为22.6314亿美元,预计到2030年将达到79.4786亿美元;预计 2022 年至 2030 年复合年增长率为 17.0%。

增加开发 ADC 的投资推动欧洲抗体药物偶联物市场

ADC 是肿瘤学领域的游戏规则改变者;这些被广泛接受用于治疗乳腺癌。多家公司正在投入巨额投资来开发新型 ADC。 2022年5月,Evotec SE宣布对Tubulis GmbH进行巨额战略股权投资,用于开发ADC。 Evotec SE 在由 Andera Partners 领投的 Tubliss B 轮融资中投资了 6400 万美元(6000 万美元)。同样,2022年6月,Spirea Limited宣布获得300万美元投资(

Europe Antibody Drug Conjugates Strategic Insights

Strategic insights for Europe Antibody Drug Conjugates involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-antibody-drug-conjugates-market-strategic-framework.webp
Get more information on this report

Europe Antibody Drug Conjugates Report Scope

Report Attribute Details
Market size in 2022 US$ 2,263.14 Million
Market Size by 2030 US$ 7,947.86 Million
Global CAGR (2022 - 2030) 17.0%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 技术
  • 可裂解接头
  • 不可裂解接头
By 应用
  • 血癌
  • 乳腺癌
  • 卵巢癌
  • 尿路上皮癌
By 分销渠道
  • 医院药房
  • 零售药房
  • 网上药房
Regions and Countries Covered 欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
Market leaders and key company profiles
  • ADC Therapeutics SA
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • ImmunoGen, Inc
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • Takeda Pharmaceutical Co Ltd
  • Get more information on this report

    Europe Antibody Drug Conjugates Regional Insights

    The regional scope of Europe Antibody Drug Conjugates refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-antibody-drug-conjugates-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Antibody Drug Conjugates Market

    1. ADC Therapeutics SA
    2. Pfizer Inc
    3. Hoffmann-La Roche Ltd
    4. ImmunoGen, Inc
    5. GSK Plc
    6. Gilead Sciences Inc
    7. AstraZeneca Plc
    8. Astellas Pharma Inc
    9. Takeda Pharmaceutical Co Ltd

    Frequently Asked Questions
    How big is the Europe Antibody Drug Conjugates Market?

    The Europe Antibody Drug Conjugates Market is valued at US$ 2,263.14 Million in 2022, it is projected to reach US$ 7,947.86 Million by 2030.

    What is the CAGR for Europe Antibody Drug Conjugates Market by (2022 - 2030)?

    As per our report Europe Antibody Drug Conjugates Market, the market size is valued at US$ 2,263.14 Million in 2022, projecting it to reach US$ 7,947.86 Million by 2030. This translates to a CAGR of approximately 17.0% during the forecast period.

    What segments are covered in this report?

    The Europe Antibody Drug Conjugates Market report typically cover these key segments-

  • 技术 (可裂解接头, 不可裂解接头)
  • 应用 (血癌, 乳腺癌, 卵巢癌, 尿路上皮癌)
  • 分销渠道 (医院药房, 零售药房, 网上药房)
  • What is the historic period, base year, and forecast period taken for Europe Antibody Drug Conjugates Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Antibody Drug Conjugates Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in Europe Antibody Drug Conjugates Market?

    The Europe Antibody Drug Conjugates Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • ADC Therapeutics SA
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • ImmunoGen, Inc
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • Takeda Pharmaceutical Co Ltd
  • Who should buy this report?

    The Europe Antibody Drug Conjugates Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Antibody Drug Conjugates Market value chain can benefit from the information contained in a comprehensive market report.